Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Lipton, J.H.; Bryden, P.; Sidhu, M.K.; Huang, H.; McGarry, L.J.; Lustgarten, S.; Mealing, S.; Woods, B.; Whelan, J.; Hawkins, N.
• Is Part Of: Leukemia research. Volume 39:Issue 1(2015:Jan.)
• Page Start: 58
• Page End: 64
• Publication Date: 2015-01
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2014.10.005
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">We compared the efficacy of ponatinib and 2G-TKIs in CP-CML after ≥1 prior 2G-TKI.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Relevant studies were identified by systematic review.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Estimated response to 2G-TKI was 22–26% versus 60% (95% CrI 52–68%) with ponatinib.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Probability of response was greater with ponatinib than with a further 2G-TKI.</p> </list-item> </list> </p> </sec> </abstract>